Bergen, Norway, 4 November 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, will be announcing its results for the third quarter
2021 on Tuesday 16 November 2021. The briefing will take place at 10:00 am CET
at:

Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslo

where BerGenBio's senior management team will provide an update on the Company
followed by a Q&A session. To attend in person please register by mail to
hanna.haug@carnegie.no

The presentation will webcast live and a link will be available at
www.bergenbio.com in the Investors/Financial Reports section. A recording will
be available shortly after the webcast has finished.

The third quarter report and presentation will be available on the Company's
website in the Investors/Financial Reports section from 7:00 am CET the same
day.

-Ends-

Contacts

Martin Olin
Chief Executive Officer, BerGenBio ASA
ir@bergenbio.com

Rune Skeie
Chief Financial Officer, BerGenBio ASA
rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition. This is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com


This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.